Doctors are using molecular testing to diagnose and treat diseases more accurately and at an earlier stage than ever before. Forensic technicians are using them to solve crimes that in some cases were committed decades ago. Pharmaceutical companies are using molecular technologies to develop novel drugs that give fresh hope to patients all over the world. And scientists are using these technologies to deepen our understanding of the building blocks of life as a basis for further progress.
QIAGEN is the world’s leading provider of innovative Sample & Assay Technologies, and a key player in the molecular biology revolution. More than one-half million customers throughout the world rely on the company’s products. QIAGEN’s sample technologies help to isolate genetic material and other molecules from biological samples such as blood, bone and tissue. These can then be analyzed using appropriate assay technologies to reveal the information concealed within. QIAGEN’s products transform raw bio- logical material into valuable molecular information according to standardized and reproducible procedures.
QIAGEN was founded by a team of scientists at Düsseldorf’s Heinrich Heine University in 1984. Just two years after it was set up, it brought to market a new method for obtaining genetic information from cells for further analysis that was much easier, faster and more reliable than previous methods. Processing time was cut from days to a few hours, meaning that processes in molecular biology could now be carried out in laboratories all over the world, and not just in universities. Since the launch of this first ready-to-use kit which contained everything needed to obtain nucleic acids from bacteria, QIAGEN has developed many other new sample and assay technologies.
QIAGEN currently has more than 4,000 employees at more than 35 sites throughout the world, and has annual sales of more than $1.25 billion. The company has more than 500 core products, which are sold in over 80 countries throughout the world in a large number of variations and combinations. The range includes ready-to-use standardized kits for many different applications, and suitable instruments for full automation of laboratory workflows. The company is constantly expanding this portfolio. High investment in growth areas is helping QIAGEN extend its leading position and open up new markets.